OBJECTIVES: Bevacizumab, known as VEGF inhibitor, has demonstrated significant activity when it is used with cytotoxic chemotherapy together in metastatic colorectal cancer(mCRC). However, bevacizumab is an expensive medication known as not cost-effectiveness with high ICER(Incremental Cost-Effectiveness Ratio) in other countries. The purpose of this study was to examine the economic efficiency of treating mCRC with bevacizumab plus chemotherapy versus chemotherapy alone from the perspective of the social aspects in Korea. METHODS: Markov model was developed to compare the cost and benefits of adding bevacizumab to oxaliplatin plus FU/ LV(FOLFOX) or capecitabine plus FU/LV(CapeOX) with FOLFOX or CapeOX alone. We searched clinical documentation, extracted median time to progression and median overall survival from each chemotherapy, and calculated the transition probability and death rate per cycle. Model simulates costs and outcomes in hypothetical cohort of metastatic colorectal cancer for 5 years with 5% discount rate. We included that direct and non-direct medical cost(2009). The ICERs were calculated from incremental life-years gained(LYG) and incremental costs between single and combination therapy. Sensitivity analyses were performed on crucial parameters. RESULTS: After markov model simulation for 5 years, FOLFOX bevacizumab gained 1.58 years/patient and FOLFOX 1.42 years/patient, whereas CapeOX bevacizumab 1.57 years/patient and CapeOX 1.31 years/patient. Total cost of FOLFOX bevacizumab, FOLFOX, CapeOX bevacizumab, CapeOX are W88,567,199($70,854), W73,938,752($59,151), W91,904,773($73,524), W43,864,530($35,092), respectively. The ICERs of additional bevacizumab when combined with FOLFOX, CapeOX were W89 ,974,151 ($71,979), W181,331,641 ($145,065), respectively, per life year gained, proving very high in both case combination therapy. Sensitivity analysis showed that the price of bevacizumab is a key parameter of its cost-effectiveness. CONCLUSIONS: As a result, it is proven that the addition of bevacizumab to FOLFOX, CapeOX in mCRC patients is expensive given clinical benefit in terms of LYG in Korea. This findings may offer one of the useful basic data selecting chemotherapy regimens in treating for mCRC.
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GE Healthcare, Buckinghamshire, UK, 2 Heron Evidence Development Ltd, Luton, UK, 3 GE Healthcare, Waukesha, WI, USA OBJECTIVES: Colorectal cancer (CRC) is the third most common cancer in the UK. In 2007 the UK NHS introduced a CRC screening programme using the faecal occult blood test (FOBT) for biennial screening of individuals aged 60 to 69. CT colonography (CTC) is an alternative technology for CRC screening with the potential to prevent cancer by detecting pre-cancerous polyps as well as detecting cancer at an early stage. This economic analysis assessed the cost-effectiveness of CTC for CRC screening from the UK NHS perspective. METHODS: A state-transition Markov model was constructed to simulate the lifetime experience of a cohort of individuals screened under a range of scenarios using four different CRC screening technologies: FOBT, flexible sigmoidoscopy, optical colonoscopy and CTC. The model estimated lifetime costs and health outcomes; the cost-effectiveness measure was incremental cost per Quality Adjusted Life Year (QALY). The impact of uncertainty in underlying model parameters was evaluated in one-way and probabilistic sensitivity analyses. RESULTS: CTC screening every 10 years for individuals aged 60-69 was less expensive and yielded greater health benefits (QALYs and life years) compared to no screening or the current UK programme of biennial FOBT screening. Compared to biennial FOBT, 10-yearly CTC screening for 60-69 year olds is estimated to avoid 661 more cases of CRC and 364 more deaths per 100,000 people invited for screening. CTC was cost-effective under a range of assumptions. The model fit to observed epidemiology data well, and was robust to changes in underlying parameter values. CONCLU-SIONS: CTC has the potential to provide a cost-effective option for CRC screening and may be cost saving compared to the current programme of biennial FOBT.
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Borget I 1 , Cadranel J 2 , Pignon JP 3 , Danton G 3 , Coudert B 4 , Dansin E 5 , Friard S 6 , Daniel C 7 , Quoix E 8 , Madeleine J 9 , Madroszyk A 10 , Morin F 11 , Chouaid C 12 1 Institut de Cancérologie Gustave Roussy, Villejuif, France, 2 Hospital Tenon, Paris, France, 3 Institut Gustave Roussy, Villejuif, France, 4 Centre Georges François Leclerc, Dijon, France, 5 Oscar Lambret hospital, Lille, France, 6 Hospital Foch, Suresnes, France, 7 Institut Curie, Paris, France, 8 CHU Strasbourg, Strasbourg, France, 9 CHU Caen, Caen, France, 10 Institut Paoli Calmette, Marseille, France, 11 IFCT, Paris, France, 12 Hopital Saint antoine, APHP, Paris, France OBJECTIVES: Although several clinical and biological parameters are prognostic factors, their medico-economic impact in the prescription of erlotinib has never been evaluated. A French NCI prospective study aimed to determine the cost of management of advanced NSCLC patients (pts) treated by erlotinib and to evaluate the costeffectiveness ratio in populations selected on clinical-guided or biomarkers-guided arguments. METHODS: Prospective cohort of consecutive advanced NSCLC pts newly treated by erlotinib and followed until progression or death. Direct medical costs, including erlotinib and hospitalization costs were computed from the health care system perspective with a time horizon of 2 years. Cost-effectiveness ratios (CER) were calculated as management cost divided by the number of days of life remaining (DOLR) when the treatment is initiated, in all patients, in clinical-selected patients (non/ex-smoking women with non-squamous cell carcinoma (SCC) histology) and in biomarker-selected patients. RESULTS: A total of 522 patients were enrolled between 522 patients were enrolled between 02/07 and 03/08. Median age was 62 years; 32% were females; 63% had adenocarcinoma. With a 15.5 months (mo.) median follow-up, median PFS and OS were respectively 2.4 and 5.6 mo. Mean management cost was 10284 mo. Mean management cost was 10284 mo. Mean management cost was 10284 a8562 per patient, with a median of 170 days remaining to live at initiation of erlotinib treatment (a60 / DOLR). Direct erlotinib cost represented 78% of the cost. Non-smoking women with non-SCC histology lived 133 days longer than other patients (279 and 146 days respectively), resulting in an extra-cost management of a2637 due to a longer erlotinib treatment. CER was however lower (a44/DOLR) in non-smoking women with non SCC histology than in other patients (a66/DOLR). CER of biomarkers-selected patients will be available for the congress. CONCLUSIONS: Clinical-guided arguments allowed to identify patients with lower management costs per day of life remaining to live. Planned analyses would evaluate the impact of biomarkers in term of cost of management per day of life remaining.
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COST-EFFECTIVENESS OF PROGNOSIS-BASED STRATEGIES TO SELECT WOMEN WITH BREAST CANCER FOR ADJUVANT CHEMOTHERAPY
Bonastre J, Koscielny S Institut Gustave Roussy, Villejuif, France OBJECTIVES: Adjuvant chemotherapy is used to reduce the risk of relapse after surgery. Its limited efficacy in breast cancer must be weighed against induced toxicities and cost. The selection of patients eligible for adjuvant chemotherapy is based on prognostic factors. Genomic signatures would improve patient selection for adju-enomic signatures would improve patient selection for adjuvant chemotherapy and avoid overtreatment. The aim of this study is to compare the and avoid overtreatment. The aim of this study is to compare the avoid overtreatment. The aim of this study is to compare the The aim of this study is to compare the cost -effectiveness of different prognosis -based selection strategies in the French context. METHODS: We used a model -based simulation. Population characteristics, survival and hospital costs (chemotherapy, chemotherapy -induced toxicities and relapses) were estimated using a patient -level data set from a retrospective cohort of patients followed -up at Gustave Roussy Institute since 1990. All patients were node -negative and metastasis -free after initial surgery. The other model parameters (chemotherapy efficacy, sensitivity and specificity of prognosis -based selection strategies) were obtained from literature. The cost analysis was conducted from a third -party payer's perspective. We used a strategy with no adjuvant chemotherapy as a reference for cost -effectiveness comparisons. RESULTS: The retrospective cohort study consisted of 910 women with breast cancer. The mean age was 57 (range: 23-93). Thirty-one percent of patients were Scarff -Bloom grade I, 43% grade II and 19% grade III (7% grade missing). The mean tumor size was 19 mm (range: 1-120). Thirty-two percent of the women received adjuvant chemotherapy alone or combined with another adjuvant treatment. The median follow-up after surgery was 87 months. The median survival time was 209 months. The distant relapse rate was 10.7%. The cost of adjuvant chemotherapy was a3,083 (standard deviation: a307) and the cost of distant relapse a33,692 (range: a847-a112,710). Cost -effectiveness analysis is in progress. Results will be available for the meeting. CONCLUSIONS: This is the first French study to assess the cost -effectiveness of using prognostic information to select women eligible for adjuvant chemotherapy in early breast cancer.
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COST-EFFECTIVENESS ANALYSIS OF IMIQUIMOD VERSUS NO TREATMENT IN PATIENTS WITH SUPERFICIAL BASAL CELL CARCINOMA AND CONTRAINDICATION TO SURGICAL INTERVENTION/CRYOTHERAPY
Walczak J, Nogas G, Dybek-Karpiuk A, Kloc K, Labak M, Pawlik D Arcana Institute, Cracow, Poland OBJECTIVES: To conduct a cost-effectiveness analysis (CEA) of imiquimod compared to no treatment in patients with superficial basal cell carcinoma and contraindication to surgical intervention and cryotherapy in Poland. METHODS: This analysis was based on a decision model regarding clinical effects of imiquimod in comparison to placebo (vehicle cream), obtained from randomized clinical trials. The population was defined as adult patients with superficial basal cell carcinoma (sBCC) and contraindication to surgical intervention/cryotherapy, also patients, who do not give consent to these forms of treatment. Clinical and histological complete clearance were assessed as health outcomes. Direct medical costs of the analysed therapies were estimated from the perspective of both payers in Poland (National Health Fund and patient). We included costs of medication, clinic visits and diagnostic assessments. Time horizon of the analysis was 18 weeks. Treatment was assumed as once a day 5x/week for 6 weeks. Costs and effects were not discounted. RESULTS: Probability of complete clearance, assessed clinically and histologically was 0.751 for patients treated with imiquimod and 0.017 when placebo was used. Probability of histological complete clearence was 0.822 and 0.031, respectively. Total costs of imiquimod therapy were estimated at 1,075.30 PLN, while costs of no treatment were 174.80 PLN. Incremental
